Semaglutide has been the most discussed medicine of the decade, and also one of the most misunderstood in terms of how New Zealanders actually access it. Here is the practical picture.

One molecule, several products

Semaglutide is sold under different brand names for different indications and at different dose ranges. Ozempic is the version licensed for type 2 diabetes, with a lower maximum dose. Wegovy is the version licensed specifically for weight management, with a higher maximum dose. Rybelsus is an oral tablet formulation, again for diabetes.

The distinction matters practically because funding, dosing and availability differ by product even though the active ingredient is the same. It also explains why you see conflicting information online: much of it refers to different products or different countries.

What it does

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating, and it does several things: signals satiety to the brain, slows the rate at which the stomach empties, and improves the insulin response to a meal.

The medication mimics that hormone with a much longer duration of action, which is why it is dosed weekly rather than after each meal. The subjective effect most people describe is not a suppressed appetite in the stimulant sense but a reduction in what many patients call food noise: the persistent low-level preoccupation with eating. Meals feel finished sooner, and thinking about the next one becomes less constant.

The clinical trial data is substantial. The STEP programme, which tested semaglutide at weight-management doses, reported average body weight reductions around 15 percent over sixty-eight weeks in participants also receiving lifestyle support. That is a considerably larger effect than any previous non-surgical option.

Access in New Zealand

Semaglutide is prescription-only. A New Zealand-registered doctor or nurse practitioner must assess you and issue the prescription.

Funding is the main constraint. Pharmac has funded semaglutide for type 2 diabetes under defined clinical criteria. Funding specifically for weight management has been much more restricted, which means most people using it for that purpose are paying privately.

The practical route for most people is either a GP willing to prescribe privately or a telehealth service running a structured weight management programme. Services offering wegovy nz consultations vary in what they include, and the comparison worth making is total annual cost including consultations, dose escalations and blood tests, not the headline monthly figure.

The supply story

Global demand for semaglutide has repeatedly exceeded manufacturing capacity since 2021. New Zealand, being a small market at the end of a long supply chain, has experienced this as intermittent shortages, sometimes affecting specific dose strengths rather than the product as a whole.

The practical implications for patients are worth understanding. A shortage at your current dose may mean holding at a lower strength temporarily, which is usually clinically acceptable but frustrating. It may mean switching to a different product, which requires a clinical conversation about equivalent dosing. What it should never mean is sourcing product from unverified overseas sellers. Counterfeit GLP-1 pens have been documented in multiple countries, some containing insulin instead of the labelled ingredient, which is genuinely dangerous.

Ask any provider directly how they handle supply interruptions before you start. A service with pharmacy relationships and a substitution plan is materially different from one that simply goes quiet.

Cost mechanics

Beyond the base price, two variables affect what you pay over a year.

The first is dose scaling. Semaglutide is titrated upward over several months, and some pricing models increase with strength while others hold flat. Over a full year of treatment this difference compounds meaningfully.

The second is what is bundled. Consultations, dose review appointments, baseline and follow-up blood tests, and courier delivery are sometimes included and sometimes billed separately. A programme at a higher monthly price that includes everything can total less than a cheaper one that does not.

Who it is not for

Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. It is not used in pregnancy or when planning pregnancy, and contraception is generally advised during treatment. A history of pancreatitis warrants caution, as does active gallbladder disease. Certain eating disorder histories require careful clinical consideration.

It also interacts with other treatments. People on insulin or sulfonylureas usually need dose adjustment to avoid hypoglycaemia. Slowed gastric emptying affects the absorption of some oral medications.

This is why the assessment matters, and why any route that skips it is not worth the money saved.

What to expect

Appetite change is usually noticeable within two to four weeks. Weight loss accumulates gradually over the following year or more. Nausea, constipation and reflux are common early and generally settle; slower dose escalation helps.

Response varies more than the trial averages suggest. Some people lose 20 percent or more of body weight. A minority lose very little despite good adherence, and there is currently no reliable way to predict which group you fall into in advance. Any provider presenting trial averages as your expected outcome is overselling.